• Modern treatment methods of intravenous immunoglobulin-resistant patients with Kawasaki disease (literature review)

Modern treatment methods of intravenous immunoglobulin-resistant patients with Kawasaki disease (literature review)

SOVREMENNAYA PEDIATRIYA.2017.6(86):120-124; doi 10.15574/SP.2017.86.120

Berezhnyi V. V., Sovtus Kh. M., Bondarets Yu. I.
Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

The article presents literature review on Kawasaki disease management in children, who are resistant to the routine treatment of intravenous immunoglobulin, administered in a dose of 2 g/kg and aspirin in dose of 30 mg/kg/day.
Key words: Kawasaki disease, intravenous immunoglobulins, resistance.

References

1. Berezhnyi VV, Sovtus KhM, Bondarets YuI. (2017). Khvoroba Kavasaki u ditei. Osoblyvosti diahnostyky ta likuvannia (lektsiia). Sovremennaia pedyatryia. 3(83): 38—44.

2. Berezhnoy V. (2015). Effektivnost ispolzovaniya immunobiologicheskogo preparata Etanertsept u detey s revmatoidnyim artritom. Sovremennaya pediatriya. 1(65): 72—82; doi 10.15574/SP.2015.65.72

3. Yokota S, Nishioka K. (2017). Poslednie dostizheniya pediatricheskoy revmatologii v Yaponii: provospalitelnyie tsitokinyi kak terapevticheskaya mishen pri bolezni Kavasaki, yuvenilnom idiopaticheskom artrite i kriopirin-assotsiirovannom periodicheskom sindrome. RMZh. 5: 380—386.

4. Maydannik VG, Mityuraeva-Korneyko IA. (2015). Bolezn Kavasaki v detskom vozraste. Nauchnoe izdanie. — Kiev: Logos: 293—295.

5. Newburger JW, Takahashi M, Gerber MA et al. (2004). Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 110: 2747. https://doi.org/10.1161/01.CIR.0000145143.19711.78; PMid:15505111

6. Mori M, Imagawa T, Hara R et al. (2012). Efficacy and limitation of Infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: Report of an open-label cases series. J Rheumatol. 39: 864—7. https://doi.org/10.3899/jrheum.110877; PMid:22337241

7. Kobayashi T, Saji T, Otani T et al. (2012). Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 379: 1613—1620. https://doi.org/10.1016/S0140-6736(11)61930-2

8. Mori M, Imagawa T, Katakura S et al. (2004). Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol. 14(1): 43—7. https://doi.org/10.3109/s10165-003-0264-3; PMid:17028804

9. Ohashi R, Fukazawa R, Watanabe M et al. (2013). Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents. Int J Vasc Med. 2013: 43141. https://doi.org/10.1155/2013/543141; PMid:23606968 PMCid:PMC3626397

10. Burns JC, Best BM, Mejias A et al. (2008). Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Pediatr. 153: 833—8. https://doi.org/10.1016/j.jpeds.2008.06.011; PMid:18672254 PMCid:PMC2856847

11. Rodriguez-Gonzalez M, Matamala-Morillo MA, Segado-Arenas A. (2014). Infliximab as rescue therapy in refractory Kawasaki disease. Ann Pediatr Cardiol. 7(1): 74—75. https://doi.org/10.4103/0974-2069.126578; PMid:24701096 PMCid:PMC3959072

12. Choueiter NF, Olson AK, Shen DD, Portman MA. (2010). Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr. 157(6): 960—966. https://doi.org/10.1016/j.jpeds.2010.06.014; PMid:20667551 PMCid:PMC2970727

13. Newburger JW, Sleeper LA, McCrindle BW et al. (2007). Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 356: 663—675. https://doi.org/10.1056/NEJMoa061235; PMid:17301297

14. Hashino K, Ishii M, Iemura M et al. (2001). Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 43: 211—217. https://doi.org/10.1046/j.1442-200x.2001.01373.x; PMid:11380911